Publications by authors named "J C Metts"

: Prior studies suggest that blood transfusion may adversely affect the survival of patients with cancer via transfusion-related immunomodulation. The objective of our study is to investigate the association between transfusion during neoadjuvant chemotherapy and survival in children, adolescent, and young adult (CAYA, 39 years old or younger) patients with osteosarcoma. : This is a multicenter retrospective cohort study of patients between 2007 and 2022.

View Article and Find Full Text PDF
Article Synopsis
  • - A Phase II trial was conducted to evaluate the combination of gemcitabine and nab-paclitaxel for treating recurrent osteosarcoma in patients aged 12-30, with an emphasis on assessing progression-free survival and identifying potential biomarkers.
  • - Eighteen patients participated, showing a 28% progression-free survival rate after four months, with some experiencing partial responses but facing dose reductions and toxicities.
  • - The study concluded that the gemcitabine and nab-paclitaxel combination has comparable effectiveness and toxicity to previous treatments with gemcitabine and docetaxel, while highlighting the potential for using circulating tumor cells and circulating tumor DNA as response biomarkers in future research.
View Article and Find Full Text PDF

Introduction: The expansion of tumor-infiltrating lymphocytes (TIL) for adoptive cellular therapy is under investigation in many solid tumors of adulthood. Marrow-infiltrating lymphocytes (MIL) have demonstrated antitumor reactivity preclinically. Successful expansion of TIL/MIL has not been reported across pediatric solid tumor histologies.

View Article and Find Full Text PDF

Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells.

View Article and Find Full Text PDF